Dr. Tom Geisbert
Dr. Tom Geisbert, Ph.D
Department of Microbiology & Immunology
GNL, Route 0610
The Geisbert laboratory focuses on the pathogenesis of emerging and re-emerging viruses that require Biosafety level 4 containment and on the development of countermeasures against these viruses. Their work emphasizes studies on viruses causing hemorrhagic fever (HF) including Ebola virus, Marburg virus, and Lassa virus. Efforts focus on: 1) developing, refining and characterizing animal models that accurately reproduce human viral HF infection; 2) identifying critical pathogenic processes of viral hemorrhagic fever infections that could be exploited as targets for therapeutic interventions. Particular emphasis is placed on determining the basis of coagulopathy and shock that characterize hemorrhagic fever viral infections; and 3) measuring the therapeutic benefits of interrupting pathogenic processes that are important in the development of HF viral infection. Currently, there are no vaccines against Ebola, Marburg, or Lassa viruses approved for use in humans. Geisbert focuses primarily on using recombinant vesicular stomatitis virus (rVSV) as a vaccine vector for viral HF. He has shown that rVSV-based HF viral vaccines can completely protect nonhuman primates against Ebola HF, Marburg HF, and Lassa fever. Specific interest areas include modifying rVSV vectors for optimal safety and immunogenicity, identifying antigens needed to develop a multiagent vaccine that can protect against major groups of HF viruses, and determining the role of cellular and host immune responses in protection.
Tom Geisbert holds a BS from Western Maryland College, a MS from Hood College Graduate School, and a PhD from Uniformed Services University of the Health Sciences, Bethesda.
- Recombinant Adenovirus Serotypes 26 and 35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates Against Ebolavirus Challenge
Geisbert TW, Bailey M, Hensley L, et al.
J Virol. 2011 Feb 16.
- Ebola haemorrhagic fever
Feldmann H, Geisbert TW.
Lancet. 2011 Mar 5;377(9768):849-62.
- Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.
Geisbert TW, Bailey M, Geisbert JB, et al.
J Virol. 2010 Oct;84(19):10386-94. Epub 2010 Jul 21.
- Prospects for immunisation against Marburg and Ebola viruses
Geisbert TW, Bausch DG, Feldmann H.
Rev Med Virol. 2010 Nov;20(6):344-57. Review.
- Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I.
Lancet. 2010 May 29;375(9729):1896-905.
- Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H.
J Virol. 2009 Jul;83(14):7296-304. Epub 2009 Apr 22.
- Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al.
PLoS Pathog. 2008 Nov;4(11):e1000225. Epub 2008 Nov 28.
- Development of vaccines for Marburg hemorrhagic fever
Bausch DG, Geisbert TW.
Expert Rev Vaccines. 2007 Feb;6(1):57-74. Review.
- Effective post-exposure treatment of Ebola infection.
Feldmann H, Jones SM, Daddario-DiCaprio KM, et al.
PLoS Pathog. 2007 Jan;3(1):e2.
- Development of a new vaccine for the prevention of Lassa fever
Geisbert TW, Jones S, Fritz EA, et al.
PLoS Med. 2005 Jun;2(6):e183. Epub 2005 Jun 28.
- Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
Jones SM, Feldmann H, Ströher U, et al.
Nat Med. 2005 Jul;11(7):786-90. Epub 2005 Jun 5.
- Exotic emerging viral diseases: progress and challenges
Geisbert TW, Jahrling PB.
Nat Med. 2004 Dec;10(12 Suppl):S110-21. Review.
- Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys
Geisbert TW, Hensley LE, Jahrling PB, et al.
Lancet. 2003 Dec 13;362(9400):1953-8.
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ.
Nature. 2003 Aug 7;424(6949):681-4.